{
    "clinical_study": {
        "@rank": "3343", 
        "arm_group": [
            {
                "arm_group_label": "group 1", 
                "arm_group_type": "Experimental", 
                "description": "age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 2", 
                "arm_group_type": "Experimental", 
                "description": "age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 3", 
                "arm_group_type": "Experimental", 
                "description": "age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 4", 
                "arm_group_type": "Experimental", 
                "description": "age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 5", 
                "arm_group_type": "Experimental", 
                "description": "age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 6", 
                "arm_group_type": "Experimental", 
                "description": "age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 7", 
                "arm_group_type": "Experimental", 
                "description": "age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 8", 
                "arm_group_type": "Experimental", 
                "description": "age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 9", 
                "arm_group_type": "Experimental", 
                "description": "age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 10", 
                "arm_group_type": "Experimental", 
                "description": "age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 11", 
                "arm_group_type": "Experimental", 
                "description": "age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 12", 
                "arm_group_type": "Experimental", 
                "description": "age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 13", 
                "arm_group_type": "Experimental", 
                "description": "age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 14", 
                "arm_group_type": "Experimental", 
                "description": "age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s"
            }, 
            {
                "arm_group_label": "group 15", 
                "arm_group_type": "Experimental", 
                "description": "age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s"
            }, 
            {
                "arm_group_label": "group 16", 
                "arm_group_type": "Experimental", 
                "description": "age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effect and safety of mivacurium chloride in pediatric patients."
        }, 
        "brief_title": "A Prospective, Multi-center, Randomized Controlled Study of Effect and Safety of Mivacurium Chloride in Pediatric Patients", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Efficacy and Safety of Mivacurium Chloride for Pediatric Patients", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The parent/guardian must sign a parental permission consent document\n\n          -  American Society of Anesthesiologists (ASA) physical status class 1-3\n\n          -  Elective surgery patients with tracheal intubation, and the operation duration is\n             expected to be longer than 30 min but no longer than 120 min(cleft lip and palate,\n             orthopedic, bilateral hernia, bilateral cryptorchidism, hypospadias crack, and other\n             ear, nose and throat surgery, etc)\n\n          -  18 Years to 80 Years\n\n        Exclusion Criteria:\n\n          -  BMI<18kg/m2  or BMI>31kg/m2\n\n          -  Patiens with serious respiratory, cardiovascular disease, and liver and kidney\n             dysfunction[AST\uff08glutamic oxalacetic transaminase\uff09,ALT(glutamic-pyruvic\n             transaminase)>1.5 Normal;BUN(blood urea nitrogen)>Normal)]\n\n          -  Patients with asthma or airway hyperresponsiveness, neuromuscular patients disease or\n             cachexia\n\n          -  Preoperative hemoglobin less than 10g/L\n\n          -  Hypoproteinemia TP\uff08total protein) <45g/L\n\n          -  Diabetic patients\n\n          -  Patients with difficulty airway\n\n          -  Patients with Known or suspected atypical plasma cholinesterase gene homozygous\n\n          -  Burn patients\n\n          -  Patients with serious acid-base imbalances, or severe electrolyte imbalance\n\n          -  Patients with neuromuscular relaxants in a week\n\n          -  Patients prohibited with muscle relaxants, or allergy to any component of mivacurium\n\n          -  Patients participated in any drug clinical trial with 30 days before the start of the\n             study\n\n          -  Other situations not suitable for inclusion\n\n          -  Blood loss more than 10 ml/kg in surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "1152", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117401", 
            "org_study_id": "20121101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2", 
                    "group 3", 
                    "group 4", 
                    "group 5", 
                    "group 6", 
                    "group 7", 
                    "group 8", 
                    "group 9", 
                    "group 10", 
                    "group 11", 
                    "group 12", 
                    "group 13", 
                    "group 14", 
                    "group 15", 
                    "group 16"
                ], 
                "description": "intravenously injected  during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.", 
                "intervention_name": "mivacurium chloride", 
                "intervention_type": "Drug", 
                "other_name": "mivacron"
            }, 
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2", 
                    "group 3", 
                    "group 4", 
                    "group 5", 
                    "group 6", 
                    "group 7", 
                    "group 8", 
                    "group 9", 
                    "group 10", 
                    "group 11", 
                    "group 12", 
                    "group 13", 
                    "group 14", 
                    "group 15", 
                    "group 16"
                ], 
                "description": "Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or  mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children\nInduction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg", 
                "intervention_name": "midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2", 
                    "group 3", 
                    "group 4", 
                    "group 5", 
                    "group 6", 
                    "group 7", 
                    "group 8", 
                    "group 9", 
                    "group 10", 
                    "group 11", 
                    "group 12", 
                    "group 13", 
                    "group 14", 
                    "group 15", 
                    "group 16"
                ], 
                "description": "mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children\nInduction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg", 
                "intervention_name": "ketamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2", 
                    "group 3", 
                    "group 4", 
                    "group 5", 
                    "group 6", 
                    "group 7", 
                    "group 8", 
                    "group 9", 
                    "group 10", 
                    "group 11", 
                    "group 12", 
                    "group 13", 
                    "group 14", 
                    "group 15", 
                    "group 16"
                ], 
                "description": "Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min", 
                "intervention_name": "propofol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2", 
                    "group 3", 
                    "group 4", 
                    "group 5", 
                    "group 6", 
                    "group 7", 
                    "group 8", 
                    "group 9", 
                    "group 10", 
                    "group 11", 
                    "group 12", 
                    "group 13", 
                    "group 14", 
                    "group 15", 
                    "group 16"
                ], 
                "description": "Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min", 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketamine", 
                "Remifentanil", 
                "Midazolam", 
                "Propofol", 
                "Mivacurium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 15, 2014", 
        "number_of_arms": "16", 
        "official_title": "A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Krieg Tracheal Intubation Score\nScore        \uff1a            1          2                  3                 4\nLaryngoscopy \uff1a           Easy      Fair            Difficult      Impossible\nVocal cords\uff1a           Open      Moving          Closing        Closed\nCoughing\uff1a              None      Diaphragm        Mild          Severe\nA total score of 3-4 = excellent, 5-7 = good, 8-10 = poor, 11-12 = bad.", 
                "measure": "intubation score", 
                "safety_issue": "No", 
                "time_frame": "1 minute within intubation"
            }, 
            {
                "description": "Recording T1 and TOFR\uff08Train of four ratio) before/after the induction of anesthesia -Onset time of Mivacurium\uff1atime from end of injection until occurrence of maxi- mum block\nDuration of clinical relaxation\uff1atime to recovery of Tl(the first response in the TOF) to 25%\nRecovery index\uff1aTime interval during with T1 recovered from 25%", 
                "measure": "muscle relaxation effect", 
                "safety_issue": "No", 
                "time_frame": "from baseline to no more than 120 minutes after intubation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Nhwa Pharmaceutical Co.,LTD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Nhwa Pharmaceutical Co.,LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}